A big step forward for personalized cancer therapies from Tübingen

👨‍🔬 👩‍🔬Members of our Cluster at Eberhard Karls Universität Tübingen & Universitätsklinikum Tübingen have tested a personalized T-cell activator for the first time in patients with chronic lymphocytic leukemia (CLL) – the most common form of 🩸blood cancer in adults. The results, now published in The Lancet Haematology, are highly promising!

💉The therapy works a bit like a custom-made vaccine: tiny protein fragments are selected individually for each patient to help their immune system recognize and attack leukemia cells. 🧬

➡️ The approach proved safe, well-tolerated, and triggered strong and long-lasting immune responses in almost all participants.

💬“This study marks a major step towards truly personalized cancer therapies, precisely tailored to each patient’s disease,” says 👩‍🔬Prof. Dr. med. Juliane S. Walz (Peptide-based Immunotherapy), iFIT Co-Spokesperson. 👨‍🔬Prof. Dr. Helmut Salih (Translational Immunology | Salihlab) iFIT's Representative for Clinical Translation, adds: “For the first time, a personalized T-cell activator has been used in CLL treatment, opening the door to a new era of immunotherapy – not only for leukemia but for other cancers, too.”

✍The first authors of the study are Jonas Heitmann, Dr. Yacine Maringer, and Susanne Jung.

We’re excited to see how this work will shape the future of individualized cancer treatment! 🌟

Check out the study: https://lnkd.in/gRuq3rAR

📸Britt Moulien (fltr): Jonas Heitmann, Helmut Salih, Juliane Walz